Keyphrases
Interleukin-6
100%
Type 2 Diabetic Patients
81%
Insulin Resistance
75%
Hyperinsulinemia
65%
Bed Rest
65%
Oral Glucose Tolerance Test
64%
Tumor Necrosis Factor-α
53%
Type 2 Diabetes Mellitus (T2DM)
51%
Hyperglycemia
49%
Insulin Sensitivity
47%
Source Evaluation
43%
Incretin Effect
43%
Gastric Emptying Rate
43%
Low-grade Inflammation
43%
Randomized Controlled Trial
43%
Erythropoietin
43%
Body Composition
43%
Obese Men
38%
Healthy Young
37%
Glucagon-like
37%
Glucose Metabolism
37%
Body Mass Index
37%
Cognitive Function
36%
Physical Activity
36%
During Exercise
34%
Insulin Response
32%
High-sensitivity C-reactive Protein (hs-CRP)
31%
Postprandial Glucose
30%
Tocilizumab
30%
Gastric Emptying
30%
Exercise Effect
30%
Glucagon
29%
Adipose Tissue
28%
Whole-body
28%
Copenhagen
28%
Cardiorespiratory Fitness
27%
Exercise Capacity
27%
Central Fatigue
26%
Area under the Curve
26%
Peripheral Insulin Sensitivity
26%
Brain Metabolism
26%
Waist Circumference
26%
Step Reduction
26%
Postprandial Glycemia
26%
Denmark
24%
Intravenous Glucose
24%
Critically Ill Patients
24%
Metabolic Syndrome
24%
Vascular Conductance
21%
School-age children
21%
Medicine and Dentistry
Interleukin 6
89%
Skeletal Muscle
51%
Insulin Sensitivity
46%
Tumor Necrosis Factor
46%
Metabolome
43%
Carbon Source
43%
Hyperinsulinemia
43%
Bed Rest
43%
Adipose Tissue
43%
Stomach Emptying
43%
Maturity Onset Diabetes of the Young
43%
Insulin Resistance
42%
Oral Glucose Tolerance Test
33%
Tocilizumab
29%
Glucagon Like Peptide 1
28%
Physical Activity
26%
Patient with Type 2 Diabetes
25%
Metabolic Syndrome
24%
Caloric Intake
24%
Overnutrition
24%
Volunteer
24%
Oxygen Consumption
23%
Glycemic Control
22%
Incretin
21%
Cortodoxone
21%
Metabolomics
21%
Methapyrilene
21%
Caloric Restriction
21%
Cardiorespiratory
21%
Sitting
21%
Exercise
21%
Fatty Acid
21%
NMR Spectroscopy
21%
Randomized Clinical Trial
21%
Secretion (Process)
21%
Low Drug Dose
21%
Receptor Blocking
21%
Lactic Acid
21%
FGF21
21%
Interleukin 6 Receptor
21%
Follistatin
21%
Endotoxemia
21%
Intermittent Fasting
21%
Hyperglycemia
21%
Abdominal Obesity
21%
Randomized Controlled Trial
21%
Visceral Fat
21%
Glucagon
20%
Magnetic Resonance Imaging
15%
